What does ACH — research and development expense mean?

This metric represents the total operating costs directly attributable to research and development activities within the specified business segment. It encompasses expenses related to drug discovery, preclinical studies, clinical trial execution, and the advancement of the company's proprietary technology platform. Monitoring this expenditure provides insight into the company's investment intensity in pipeline innovation and its commitment to bringing next-generation precision medicines to market.

Tyra Biosciences, Inc. TYRA ACH — Research And Development Expense

Other segment segments

Personnel Costs

$11.79M+46.9%

IRNMIBC

$5.25M+307%

FGFR Discovery

$2.53M-19.2%

LGUTUC

$2.44M—

Facilities And Other Costs

$1.63M+16.3%

MUC

$1.61M-50.4%

Other Development Programs

$849K+65.2%

Similar metrics at other companies

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

QRVOACG — Research and Development Expense

$92.43M-3.4%

Other financials

Income statement

See full

Operating income-$42.0M-31.9%

Net income-$39.3M-39.6%

EPS (diluted)-$0.64-36.2%

Balance sheet

See full

Cash & equivalents$85.0M-15.7%

Total debt$5.7M-6.9%

Total equity$387.6M+19.8%

Total assets$412.0M+20.0%

Cash flow

See full

Operating cash flow-$32.6M-27.9%

CapEx$88.0K+529%

Free cash flow-$32.7M-28.2%

Valuation

See full

Market cap$1.79B+318%

Enterprise value$1.71B+397%

Returns & leverage

See full

Return on equity-36.9%+21.1pp

Debt / equity0×0.0×

Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s ach — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s ACH — research and development expense?: Tyra Biosciences, Inc. (TYRA) reported ACH — research and development expense of $4.31M in Q1 2026.
What does ACH — research and development expense mean?: This metric represents the total operating costs directly attributable to research and development activities within the specified business segment. It encompasses expenses related to drug discovery, preclinical studies, clinical trial execution, and the advancement of the company's proprietary technology platform. Monitoring this expenditure provides insight into the company's investment intensity in pipeline innovation and its commitment to bringing next-generation precision medicines to market.